RAS Drug Nearly Doubles Survival in Mets Pancreatic Cancer

Published Date: 04 Jun 2026

In a 500-patient phase 3 trial, daraxonrasib extends median overall survival to 13.2 vs 6.7 months for chemotherapy in second-line metastatic pancreatic cancer.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Alternative breast imaging techniques beyond mammography.

2.

Researchers use genomic technology to investigate aggressive skin cancer linked to burn scars

3.

Capivasertib Wins Metastatic Prostate Cancer Approval

4.

Fixed-Duration Combo Shows Promise for Relapsed MCL

5.

Q&A: Breast cancer facts that could save lives


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot